MGMT and glioma: The presence of some biomarkers, such as mutant IDH, O6-methylguanine DNA methyltransferase (MGMT) promoter methylation, epidermal growth factor receptor amplification and p53 mutation, have predictive and diagnostic potential in gliomas (42).